Key result
Replacing Cys 347 with alanine or serine in mCAT-2A rendered the transporter insensitive to inhibition by nitric oxide, identifying the -SH moiety of Cys 347 as responsible for NO regulation.
Why the study?
The molecular mechanism by which nitric oxide acutely and directly modulates cationic amino acid transporter CAT-2A activity through cysteine residue modification was unclear.
The study identifies Cys 347 as the critical residue responsible for nitric oxide-mediated inhibition of the mCAT-2A transporter, providing a potential molecular target for therapeutic intervention.
Cationic amino acid transporters (CATs) supply cells with essential and semiessential dibasic amino acids. Among them, l -arginine is the substrate for nitric oxide synthases (NOS) to produce nitric oxide (NO), a key signaling molecule and second messenger. In cardiac preparations, we showed that NO acutely and directly modulates transport activity by noncompetitively inhibiting these CATs. We hypothesize that this NO regulation occurs through modification of cysteine residues in CAT proteins. Homology modeling and a computational chemistry approach identified Cys 347 as one of two putative targets for NO binding, of 15 Cys residues present in the low-affinity mouse CAT-2A (mCAT-2A). To test this prediction, mammalian cell lines overexpressing mCAT-2A were used for site-directed mutagenesis and uptake studies. When Cys 347 was replaced with alanine (Cys 347 Ala), mCAT-2A became insensitive to inhibition by NO donors. In addition, the transport capacity of this variant decreased by >50% compared to that of the control, without affecting membrane expression levels or apparent affinities for the transported amino acids. Interestingly, replacing Cys 347 with serine (Cys 347 Ser) restored uptake levels to those of the control while retaining NO insensitivity. Other Cys residues, when replaced with Ala, still produced a NO-sensitive CAT-2A. In cells co-expressing NOS and mCAT-2A, exposure to extracellular l -arginine inhibited the uptake activity of control mCAT-2A, via NO production, but not that of the Cys 347 Ser variant. Thus, the -SH moiety of Cys 347 is largely responsible for mCAT-2A inhibition by NO. Because of the endogenous NO effect, this modulation is likely to be physiologically relevant and a potential intervention point for therapeutics.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2020) studied this question. Site-directed mutagenesis of Cys 347 (Cys 347 Ala or Cys 347 Ser) vs. Control mCAT-2A was evaluated on Sensitivity to inhibition by NO donors and transport capacity. Replacing Cys 347 with alanine or serine in mCAT-2A rendered the transporter insensitive to inhibition by nitric oxide, identifying the -SH moiety of Cys 347 as responsible for NO regulation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: